Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced.

ABSTRACT:

Aims

Baseline body mass index (BMI) and weight loss promoted by sodium-glucose cotransporter 2 inhibitors may impact outcomes in patients with heart failure with reduced ejection fraction (HFrEF). We assessed in the EMPEROR-Reduced population treated with empagliflozin versus placebo the relationship between baseline BMI, weight loss and effects on the primary (time to first hospitalization for heart failure [HHF] or cardiovascular death) and key secondary outcomes.

Methods and results

We categorized patients according to their baseline BMI: <20 kg/m² (n = 180); 20 to <25 kg/m² (n = 1038); 25 to <30 kg/m² (n = 1345); 30 to <35 kg/m² (n = 774) and ≥35 kg/m² (n = 393). The treatment effect of empagliflozin on the primary o

SUBMITTER: Anker SD 

PROVIDER: S-EPMC10098519 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature